Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

UNCOVERED: Aytu bioscience s return on capital employed overview - The Untold Story

According to data from Benzinga Pro, during Q2, Aytu BioScience's (NASDAQ:AYTU) reported sales totaled $23.12 million. Despite a 58.54% increase in earnings, the company posted a loss of $11.55 million. Aytu BioScience collected $21.90 million in revenue during Q1, but reported earnings showed a $27.85 million loss.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.